



Cempra, Inc.
 Investor Relations Department
 6320 Quadrangle Drive Suite 360
 Chapel Hill, NC 27517
 United States

Visit IR website [↗](#)
 Sign-up for email alerts [↗](#)

| | |
|----------------------------------|----------------------------|
| NASDAQ: CEMP ¹ | |
| Last Trade: | 3.15 |
| Trade Time: | 4:00 PM ET Sep 25, 2017 |
| Change: | 0.00 (0.000%) |
| Day Range | N/A - N/A |
| 52-Week Range | 2.55 - 26.95 |
| Volume | N/A |
| Market Cap. (\$M) | 165.407 |
| Shares Out (M) | 52.510 |

¹ The stock information is provided by eSignal, stock charts are provided by EDGAR Online. Stock information is delayed approximately 20 minutes.

Company Profile

Cempra, Inc. is a clinical-stage pharmaceutical company focused on developing antibacterials to meet critical medical needs. Two lead antibacterial products, both in the treatment of infectious diseases, address the urgent and increasing need for new treatments targeting drug-resistant bacterial infections in both the hospital and the community.... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

Sep 7, 2017
[Cempra Announces Presentations at Upcoming Investor Conferences and Provides Merger Process Update](#)

Aug 9, 2017
[Cempra Provides Corporate Update and Reports Second Quarter 2017 Financial Results](#)

Aug 9, 2017
[Cempra and Melinta Announce Merger to Form a Leading, Vertically Integrated Commercial-Stage Anti-Infectives Company](#)

Jul 20, 2017
[Cempra to Report Second Quarter 2017 Financial Results](#)

Jun 2, 2017
[Eight Presentations at ASM Microbe Include Late Breaker From Cempra's Phase 3 Fusidic Acid Study and Solithromycin Data on Gonorrhea and Otitis Media](#)

Events [\[View all \]](#)

Sep 26, 2017
[Ladenburg Thalmann 2017 Healthcare Conference](#)

Financials [\[View all \]](#)

[Second Quarter Financial Results](#)